Sanofi’s Multaq found effective in atrial fibrillation study
The drug has showed a significant decrease in the risk of cardiovascular death by 30% (p=0.03) on top of standard therapy, including rate control and antithrombotic drugs, in
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
With the aim to transition the industry from speech recognition to speech understanding, the agreement will incorporate M Modal’s advanced speech technology, AnyModal Conversational Documentation Services (CDS), as